Phase II study comparing BCD-085 head-to-head with another IL-17 inhibitor.
Phase of Trial: Phase III
Latest Information Update: 02 May 2018
At a glance
- Drugs BCD 085 (Primary) ; Interleukin-17 inhibitors
- Indications Ankylosing spondylitis; Plaque psoriasis
- Focus Therapeutic Use
- 02 May 2018 New trial record
- 26 Apr 2018 According to Biocad media release, company plans to initiate this trial in 2019.